Tango Therapeutics, Inc. — fact timeline

Tango Therapeutics, Inc. shareholders approved Non-binding advisory vote to approve named executive officer compensation at the 2026-06-04 meeting.

“The Company's stockholders approved the non-binding, advisory vote on the compensation of the Company's named executive officers.”

Tango Therapeutics, Inc. shareholders approved Ratification of the selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-04 meeting.

“The selection of PricewaterhouseCoopers, LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 was ratified.”

Tango Therapeutics, Inc. shareholders approved Election of Mace Rothenberg, M.D. as Class II director at the 2026-06-04 meeting.

“Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.”

Tango Therapeutics, Inc. shareholders approved Election of Malte Peters, M.D. as Class II director at the 2026-06-04 meeting.

“Malte Peters, M.D. and Mace Rothenberg, M.D. were duly elected to the Company's Board as Class II directors.”

Sung Lee was appointed as Lead Independent Director, Chairperson of the Compensation Committee, Member of NCG Committee at Tango Therapeutics, Inc..

“the Board appointed Sung Lee as Lead Independent Director of the Board and the Chairperson of the Compensation Committee and as a member thereof, each effective as of May 13, 2026.”

Kanishka Pothula resigned as Director, Member of the Nominating and Corporate Governance Committee at Tango Therapeutics, Inc..

“Also on May 12, 2026, Kanishka Pothula resigned from the Board and as a member of the Nominating and Corporate Governance Committee of the Board (the “NCG Committee”), in each case effective as of May 13, 2026.”

Alexis Borisy resigned as Director, Lead Independent Director, Chairperson of the Compensation Committee at Tango Therapeutics, Inc..

“On May 12, 2026, Alexis Borisy resigned from the Company’s Board of Directors (the “Board”), as Lead Independent Director of the Board, and as the Chairperson of the Compensation Committee of the Board (the “Compensation Committee”) and as a member thereof, in each case effective as of May 13, 2026.”

Daniella Beckman departed as Chief Financial Officer at Tango Therapeutics, Inc..

“on April 10, 2026, the board of directors (the “Board”) of Tango Therapeutics, Inc. (the “Company”) determined that Daniella Beckman will no longer serve as the Company’s Chief Financial Officer, principal accounting officer and principal financial officer, effective as of April 15, 2026.”

Tango Therapeutics, Inc.: Amendment to increase authorized shares of common stock from 200,000,000 to 400,000,000 (effective 2025-06-05).

“The certificate of amendment of the Company’s Second Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), was filed with the Secretary of State of the State of Delaware on June 5, 2025 and became effective upon filing.”

Tango Therapeutics, Inc. reported the first quarter ended March 31, 2024 results: revenue $6.5 million, net income $37.9 million, EPS $0.35 per share.

“held $343.6 million in cash, cash equivalents and marketable securities, which the Company expects to be sufficient to fund operations into late 2026. Collaboration revenue was $6.5 million for the three months ended March 31, 2024, compared to $5.8 million for the same period in 2023. Research costs incurred under the collaboration were similar during each of the”

Tango Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2023.

“On March 18, 2024, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter and year ended December 31, 2023.”